Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436239 · ClinicalTrials.gov registry record · Phase 3
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT02436239 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 330 participants.
The verdict
NCT02436239, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
Interventions
- DRUG Vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2015-05-02 |
| Est. Completion | 2018-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436239
The ClinicalTrials.gov registry entry for NCT02436239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vilazodone is the first listed.
NCT02436239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02436239 about?
NCT02436239 is a clinical study titled "A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder". The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
What is the current status of trial NCT02436239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2015-05-02. Estimated completion is 2018-07-23.
What interventions are being tested in trial NCT02436239?
The interventions under investigation include: Vilazodone (DRUG).
Who is sponsoring clinical trial NCT02436239?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.